Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$11.06 USD
+0.08 (0.68%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.07 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Zentalis Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -292.31 | -237.11 | -166.09 | -118.55 | -46.38 |
Depreciation/Amortization & Depletion | -11.77 | -2.30 | 1.45 | 0.72 | 0.11 |
Net Change from Assets/Liabilities | 5.86 | 13.25 | 16.56 | 7.84 | 6.51 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 90.39 | 62.41 | -6.01 | 23.16 | 0.62 |
Net Cash From Operating Activities | -207.82 | -163.75 | -154.09 | -86.83 | -39.14 |
Property & Equipment | -0.58 | -2.55 | -6.11 | -0.76 | -0.35 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -43.87 | -111.63 | 2.31 | -284.07 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -14.32 | 0.00 | 0.00 |
Net Cash from Investing Activities | -44.46 | -114.18 | -18.12 | -284.83 | -0.35 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 237.30 | 261.04 | 179.67 | 342.02 | 81.88 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.15 | 18.42 | -0.05 |
Net Cash from Financing Activities | 237.30 | 261.04 | 178.52 | 360.44 | 81.83 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -14.98 | -16.89 | 6.31 | -11.22 | 42.34 |
Cash at Beginning of Period | 45.70 | 62.58 | 56.27 | 67.49 | 25.15 |
Cash at End of Period | 30.72 | 45.70 | 62.58 | 56.27 | 67.49 |
Diluted Net EPS | -4.47 | -4.48 | -3.72 | -4.19 | NA |
Fiscal Year End for Zentalis Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -292.31 | -231.37 | -175.83 | -63.26 |
Depreciation/Amortization & Depletion | NA | -11.77 | -7.55 | -5.78 | -2.90 |
Net Change from Assets/Liabilities | NA | 5.86 | -4.40 | -9.18 | -4.02 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 90.39 | 76.10 | 62.23 | 20.90 |
Net Cash From Operating Activities | NA | -207.82 | -167.22 | -128.56 | -49.28 |
Property & Equipment | NA | -0.58 | -0.41 | -0.32 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -43.87 | -1.99 | 115.37 | 42.12 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -44.46 | -2.40 | 115.05 | 42.12 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 237.30 | 237.30 | 236.99 | 0.37 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 237.30 | 237.30 | 236.99 | 0.37 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -14.98 | 67.68 | 223.49 | -6.79 |
Cash at Beginning of Period | NA | 45.70 | 45.70 | 45.70 | 45.70 |
Cash at End of Period | NA | 30.72 | 113.38 | 269.19 | 38.91 |
Diluted Net EPS | NA | -0.76 | -0.79 | -1.85 | -1.07 |